<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02368353</url>
  </required_header>
  <id_info>
    <org_study_id>D14-P008</org_study_id>
    <nct_id>NCT02368353</nct_id>
  </id_info>
  <brief_title>&quot;Stress in At Risk Mental State: Efficacy of Stress Management Cognitive Behavioral Therapy : a Randomized Controlled Trial&quot;</brief_title>
  <acronym>START</acronym>
  <official_title>Stress in At Risk Mental State: Efficacy of Stress Management Cognitive Behavioral Therapy : a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier St Anne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier St Anne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The first psychotic episodes are preceded by a pauci-symptomatic phase from 2 to 4 years
      during which the psychotic symptoms are present at a subliminal level in severity or in
      frequency. The clinical criteria &quot;mental status with risk&quot; (AR) identifies patients among
      whom 10 in 40 % will make a psychotic transition in the year.

      Our hypothesis is that interventions to reduce reactivity to stress are effective in reducing
      the intensity of psychotic symptoms in subjects with prodromal psychotic symptoms. Our
      project is to evaluate a therapy for stress management in at risk patients, compared to a
      conventional monitoring, and implement a longitudinal follow-up concerning the reduction of
      psychotic symptoms in conjunction with other markers of stress. Nonstigmatizing, these
      interventions offer an alternative to antipsychotics all the more interesting since they
      should also reduce the risk of depression and suicide.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 13, 2015</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">February 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The score at month 6 on the &quot;positive&quot; psychotic dimension of the CAARMS (first subscale including delusion, hallucination and disorganized thoughts).</measure>
    <time_frame>Month 6</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Score on CAARMS</measure>
    <time_frame>Month 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score on CAARMS</measure>
    <time_frame>Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score on CAARMS</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>· Rate of conversion (as defined by CAARMS)</measure>
    <time_frame>Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>· Rate of conversion (as defined by CAARMS)</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score on BPRS</measure>
    <time_frame>Month 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score on BPRS</measure>
    <time_frame>Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score on BPRS</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score on MADRS</measure>
    <time_frame>Month 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score on MADRS</measure>
    <time_frame>Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score on MADRS</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score on YMRS</measure>
    <time_frame>Month 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score on YMRS</measure>
    <time_frame>Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score on YMRS</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score on SOFAS</measure>
    <time_frame>Month 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score on SOFAS</measure>
    <time_frame>Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score on SOFAS</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stress marker : saliva cortisol level</measure>
    <time_frame>Month 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stress marker : saliva cortisol level</measure>
    <time_frame>Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stress marker : saliva cortisol level</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stress marker : telomerase activity</measure>
    <time_frame>Month 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stress marker : telomerase activity</measure>
    <time_frame>Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stress marker : telomerase activity</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stress marker : epigenetic markers</measure>
    <time_frame>Month 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stress marker : epigenetic markers</measure>
    <time_frame>Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stress marker : epigenetic markers</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stress marker : genetic variants that modulate stress response</measure>
    <time_frame>Month 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stress marker : genetic variants that modulate stress response</measure>
    <time_frame>Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stress marker : genetic variants that modulate stress response</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stress marker : hippocampal volume</measure>
    <time_frame>Month 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stress marker : hippocampal volume</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance score on autobiographic memory</measure>
    <time_frame>Month 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance score on autobiographic memory</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance score on sense of self tasks</measure>
    <time_frame>Month 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance score on sense of self tasks</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Young Subjects With at Risk Mental States</condition>
  <arm_group>
    <arm_group_label>Cognitive behavioral therapy group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>weekly group stress-management CBT (SM-CBT) - 1/week 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>weekly supportive therapy - 1/week 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cognitive behavioral therapy</intervention_name>
    <arm_group_label>Cognitive behavioral therapy group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Supportive therapy</intervention_name>
    <arm_group_label>Reference group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 15 to 25 years

          -  Help-seekers in one of the specialized clinics for adolescents or young adults 9

          -  Meets CAARMS criteria for 'at risk mental state' (ARMS)

        Exclusion Criteria:

          -  situations of emergency.

          -  prengnancy, breast-feeding

          -  Forced hospitalization or individuals under legal guardianship.

          -  schizophrenia (DSMIV-TR criteria)

          -  Low IQ (&lt;70) ,

          -  Mother tongue and primary educational language other than French

          -  Blindness, deafness, muteness, sensorimotor or language deficits

          -  any severe medical condition,

          -  Daily cannabis use in the last week

          -  Current depression (&gt;20 MADRS scale)

          -  Substance dependence or abuse (except nicotine) for more than 5 years.

          -  Treatments by benzodiazépine (&gt; 10 mg amount diazépam) or stop of less than 5 days

          -  Previous treatment by antipsychotics in a superior dose in more than 100 mg equivalent
             Chlorpromazine if at least a sequence lasted more than 12 weeks

          -  Treatment by antipsychotics measures &gt; 100 mg eq. CPZactuel (superior dose in more
             than 100 mg equivalent Chlorpromazine) so introduced for less than three weeks

          -  Antidepressant treatmentsbegun for less three weeks

          -  Treatment by corticoids (except local treatment)

          -  Exclusion period of another study;

          -  The usual contraindications for MRI

          -  Absence of social insurance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Marie-Odile KREBS KREBS, MD, PhD</last_name>
    <phone>0033145658646</phone>
    <email>mo.krebs@ch-sainte-anne.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marie GODARD</last_name>
    <phone>0033145657728</phone>
    <email>m.godard@ch-sainte-anne.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier Sainte Anne</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Odile KREBS, MD, PhD</last_name>
      <phone>00331 45 65 86 46</phone>
      <email>mo.krebs@ch-sainte-anne.fr</email>
    </contact>
    <contact_backup>
      <last_name>Marie GODARD</last_name>
      <phone>0033145657728</phone>
      <email>m.godard@ch-sainte-anne.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 6, 2015</study_first_submitted>
  <study_first_submitted_qc>February 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2015</study_first_posted>
  <last_update_submitted>October 18, 2017</last_update_submitted>
  <last_update_submitted_qc>October 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

